Mirati gets OPDP untitled letter for misrepresenting cancer drug efficacy
Regulatory NewsFerdous Al-Faruque
PharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)Regulatory NewsFerdous Al-FaruquePharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)